

# Investigating Metabolic and Molecular Ecological Evolution of Opportunistic Pulmonary Fungal Coinfections

Njovu, Israel Kiiza; Nalumaga, Pauline Petra; Ampaire, Lucas; Nuwagira, Edwin; Mwesigye, James; Musinguzi, Benson; Kassaza, Kennedy; Taseera, Kabanda; Kiguli Mukasa, James; Bazira, Joel; Iramiot, Jacob Stanley; Baguma, Andrew; Bongomin, Felix; Kwizera, Richard; Achan, Beatrice; Cox, Michael J; King, Jason S; May, Robin; Ballou, Elizabeth R; Itabangi, Herbert

DOI:

[10.2196/48014](https://doi.org/10.2196/48014)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Njovu, IK, Nalumaga, PP, Ampaire, L, Nuwagira, E, Mwesigye, J, Musinguzi, B, Kassaza, K, Taseera, K, Kiguli Mukasa, J, Bazira, J, Iramiot, JS, Baguma, A, Bongomin, F, Kwizera, R, Achan, B, Cox, MJ, King, JS, May, R, Ballou, ER & Itabangi, H 2023, 'Investigating Metabolic and Molecular Ecological Evolution of Opportunistic Pulmonary Fungal Coinfections: Protocol for a Laboratory-Based Cross-Sectional Study', *JMIR Research Protocols*, vol. 12, e48014. <https://doi.org/10.2196/48014>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Protocol

# Investigating Metabolic and Molecular Ecological Evolution of Opportunistic Pulmonary Fungal Coinfections: Protocol for a Laboratory-Based Cross-Sectional Study

Israel Kiiza Njovu<sup>1</sup>; Pauline Petra Nalumaga<sup>1</sup>; Lucas Ampaire<sup>2</sup>; Edwin Nuwagira<sup>3</sup>; James Mwesigye<sup>1</sup>; Benson Musunguzi<sup>4</sup>; Kennedy Kassaza<sup>1</sup>; Kabanda Taseera<sup>1</sup>; James Kiguli Mukasa<sup>5</sup>; Joel Bazira<sup>1</sup>; Jacob Stanley Iramiot<sup>6</sup>; Andrew Baguma<sup>7</sup>; Felix Bongomin<sup>8</sup>; Richard Kwizera<sup>9</sup>; Beatrice Achan<sup>10</sup>; Michael J Cox<sup>11</sup>; Jason S King<sup>12</sup>; Robin May<sup>11</sup>; Elizabeth R Ballou<sup>13</sup>; Herbert Itabangi<sup>1,6</sup>

<sup>1</sup>Medical Mycology Unit, Department of Microbiology, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda

<sup>2</sup>Department of Medical Laboratory Sciences, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda

<sup>3</sup>Department of Internal Medicine, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda

<sup>4</sup>Department of Medical Laboratory Science, Faculty of Health Sciences, Muni University, Arua, Uganda

<sup>5</sup>Department of Microbiology and Immunology, School of Health Sciences, Soroti University, Soroti, Uganda

<sup>6</sup>Mycology Unit, Department of Microbiology and Immunology, Busitema University, Mbale, Uganda

<sup>7</sup>Department of Microbiology, School of Medicine, Kabale University, Kabale, Uganda

<sup>8</sup>Department of Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda

<sup>9</sup>Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda

<sup>10</sup>Department of Microbiology, School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda

<sup>11</sup>Institute of Microbiology and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

<sup>12</sup>School of Biosciences, Sheffield University, Sheffield, United Kingdom

<sup>13</sup>Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom

**Corresponding Author:**

Herbert Itabangi

Mycology Unit

Department of Microbiology and Immunology

Busitema University

PO BOX 1460

Mbale

Uganda

Phone: 256 775554564

Email: [hitabangi@gmail.com](mailto:hitabangi@gmail.com)

## Abstract

**Background:** Fungal-bacterial cocolonization and coinfections pose an emerging challenge among patients suspected of having pulmonary tuberculosis (PTB); however, the underlying pathogenic mechanisms and microbiome interactions are poorly understood. Understanding how environmental microbes, such as fungi and bacteria, coevolve and develop traits to evade host immune responses and resist treatment is critical to controlling opportunistic pulmonary fungal coinfections. In this project, we propose to study the coexistence of fungal and bacterial microbial communities during chronic pulmonary diseases, with a keen interest in underpinning fungal etiological evolution and the predominating interactions that may exist between fungi and bacteria.

**Objective:** This is a protocol for a study aimed at investigating the metabolic and molecular ecological evolution of opportunistic pulmonary fungal coinfections through determining and characterizing the burden, etiological profiles, microbial communities, and interactions established between fungi and bacteria as implicated among patients with presumptive PTB.

**Methods:** This will be a laboratory-based cross-sectional study, with a sample size of 406 participants. From each participant, 2 sputa samples (one on-spot and one early morning) will be collected. These samples will then be analyzed for both fungal and bacterial etiology using conventional metabolic and molecular (intergenic transcribed spacer and 16S ribosomal DNA-based polymerase chain reaction) approaches. We will also attempt to design a genome-scale metabolic model for pulmonary microbial communities to analyze the composition of the entire microbiome (ie, fungi and bacteria) and investigate host-microbial interactions

under different patient conditions. This analysis will be based on the interplays of genes (identified by metagenomics) and inferred from amplicon data and metabolites (identified by metabolomics) by analyzing the full data set and using specific computational tools. We will also collect baseline data, including demographic and clinical history, using a patient-reported questionnaire. Altogether, this approach will contribute to a diagnostic-based observational study. The primary outcome will be the overall fungal and bacterial diagnostic profile of the study participants. Other diagnostic factors associated with the etiological profile, such as incidence and prevalence, will also be analyzed using univariate and multivariate schemes. Odds ratios with 95% CIs will be presented with a statistical significance set at  $P < .05$ .

**Results:** The study has been approved by the Mbarara University Research Ethic Committee (MUREC1/7-07/09/20) and the Uganda National Council of Science and Technology (HS1233ES). Following careful scrutiny, the protocol was designed to enable patient enrollment, which began in March 2022 at Mbarara University Teaching Hospital. Data collection is ongoing and is expected to be completed by August 2023, and manuscripts will be submitted for publication thereafter.

**Conclusions:** Through this protocol, we will explore the metabolic and molecular ecological evolution of opportunistic pulmonary fungal coinfections among patients with presumptive PTB. Establishing key fungal-bacterial cross-kingdom synergistic relationships is crucial for instituting fungal bacterial coinfecting etiology.

**Trial Registration:** ISRCTN Registry ISRCTN33572982; <https://tinyurl.com/caa2nw69>

**International Registered Report Identifier (IRRID):** DERR1-10.2196/48014

(*JMIR Res Protoc* 2023;12:e48014) doi: [10.2196/48014](https://doi.org/10.2196/48014)

## KEYWORDS

pulmonary mycoses; fungal-bacterial coinfection; metabolic; evolutionary; opportunistic infections; cross-kingdom interaction; tuberculosis

## Introduction

### Overview

Fungi are ecologically regarded as environmental saprophytes that feed on decaying organic matter. However, over the past 30 years, fungi have transitioned into key etiological agents for difficult-to-manage infections, killing at least 1 million people each year. Yet they remain among the most neglected diseases worldwide [1,2]. The most serious invasive fungal infections often occur in the immunocompromised patients, such as those with HIV, cancer, and organ transplant, all of which have increased dramatically in the last 20 years [2]. Clinical manifestations of fungal infections have ranged from superficial to disseminated diseases with rates of invasive opportunistic fungal infections having upsurged during recent decades. Opportunistic pulmonary fungal coinfections are also emerging due to recent changing trends in predisposing factors and etiology. In Africa, pulmonary fungal coinfections are reported in about 15%-35% of cases, mainly within the cohort of individuals coinfecting with HIV and tuberculosis (TB) [3,4]. This is posing enormous challenges to health care professionals, especially in resource-limited settings, where the diagnosis is not precise.

The chronic pulmonary disease has been linked with fungal etiology in the past but is often ignored. However, there is an emerging and interesting twist to fungal etiology, where cross-kingdom interactions appear to impact fungal virulence but are not fully explored. For instance, there are reports that bacteria can influence eukaryotic biology through various roles, such as parasites, commensals, or beneficial symbionts, in addition to acting as sources of new genetic sequences through subtle mechanisms like horizontal gene transfer [4-7]. In this context, the coexistence of fungi with other microbes, such as bacteria, in the same infection niche may unveil highly

coordinated metabolic or molecular interaction profiles. This has been shown in chronic wound infections, where fungal-bacterial coexistence disrupts the highly controlled sequence of wound healing [3,8]. In fact, chronic wound microbiome and mycobiome studies reveal that fungal coinfections contribute to impaired wound healing [8]. A study by Mucunguzi and colleagues [9] reported a 22.2% prevalence of pulmonary fungal infections among people living with HIV in Southwestern Uganda. Therefore, it is possible that fungi also affect the outcome of chronic pulmonary diseases but are missed due to the lack of specific clinical or diagnostic signatures, leading to high rates of morbidity and mortality [3,10,11].

In the immunocompromised cohort, pulmonary infections can be exacerbated by a range of pulmonary opportunistic fungal coinfections. Unfortunately, infected individuals often present with symptoms similar to those of the most prevalent diseases, such as pulmonary tuberculosis (PTB) or bacterial pneumonia [3]. This propagates their rapid spread and augments poor prognosis. Hitherto, fungi co-isolated with bacteria have been considered irrelevant and often regarded as environmental contaminants [12]. This is further worsened by limited exposure of clinicians and laboratory fraternity to fungal infection biology. Nevertheless, patients could benefit from the definitive diagnosis of these infections and an exploration of the underlying mechanisms that drive saprophytic fungi to cause diseases in this patient population.

The changing trend of fungal etiology calls for the employment of advanced technology in profiling etiological agents. The synergistic ability of fungi to interact with other microbes, such as bacteria, in health and disease proves complex and can unveil new etiological agents and highlight novel virulence traits and antimicrobial targets. In this project, we propose to study the coexistence of fungal and bacterial microbial communities

during chronic pulmonary disease, with a keen interest in underpinning fungal etiological evolution and the predominating interaction relationships that may exist between fungi and bacteria. There is already evidence that such interactions may culminate into properties distinct from those of their individual consortia [4,7,13-17]. Three hypotheses define this study, specifically that the following: (1) the burden of opportunistic pulmonary fungal coinfections is higher than what culture-dependent data suggest; (2) culture-independent data complement culture-dependent data in supporting therapeutic decisions; and (3) fungal-bacterial coexistence influences fungal and bacterial virulence. Thus, through these questions, we hope to reveal elusive interplays between the 2 microbial communities during disease development to explain differences in patient outcomes.

### Significance of the Study

Through this study, we can improve diagnosis and enhance clinical relevance as well as our epidemiological understanding of cross-kingdom etiological interactions. Pilot explorations of polymicrobial interactions, including bacterial-fungal interactions, can mediate a shift in substrate consumption, enzyme production, sexuality, thermostolerance, antimicrobial resistance, metabolism, and virulence [4,7,17-26]. For instance, some Mucorales fungi harbor bacterial endosymbionts that significantly modulate their metabolic profiles and virulence attributes in plants [16,17,27,28]; a similar interaction strategy is suggested in animal hosts [29,30].

During blight light disease of rice seedlings, a saprophytic fungus, *Rhizopus microsporus*, benefits from a toxicogenic alliance formed between this fungus and its endosymbiont bacteria, *Burkholderia rhizoxinica* or *Burkholderia endofungorum*; this alliance enables them to produce a potent anti-beta-tubulin toxin rhizoxin, which is a hepatotoxic cyclopeptide [17,27,31]. In addition, a range of phytotoxins with the potential to mediate virulence, which is thought to be produced by fungi, is a consequence of such interaction [16].

Although the impact of such relationships on clinical outcomes remains unclear, we recently demonstrated that another bacterial endosymbiont, *Ralstonia pickettii*, enabled *Rhizopus microsporus* to modulate innate immune responses in an animal model via a novel secreted factor [29,30]. Removing the endosymbiont using antibiotics rendered *Rhizopus microsporus* completely avirulent. These bioactive compounds are, therefore, important for fungal virulence as well as having potentially exploitable activities as demonstrated by the long history of fungal natural products in medicine, agriculture, and research [32].

### Study Aims

This study aims to determine and characterize the burden, etiological profiles, microbial communities, and interaction relationships established between fungi and bacteria implicated in pulmonary fungal coinfections.

## Methods

### Study Design

This study will be a laboratory-based observational cross-sectional study.

### Study Setting and Population

The study is being conducted at Mbarara Regional Referral and Teaching Hospital (MRRH) in Southwestern Uganda among patients suspected of having PTB.

### Selection Criteria

The target population under study consists of patients suspected of TB at MRRH. Participants will be included if they are 18 years and older, provide consent, and have at least one of the following qualities: presenting with PTB-like symptoms, having no prior history of TB, testing positive or negative on smear test and GeneXpert test, exhibiting lipoarabinomannan antigen positivity along with persistent respiratory symptoms, and being on anti-TB treatment and severely ill yet able to produce sputum. Conversely, HIV-positive or HIV-negative patients who have TB-like symptoms but are on anti-TB treatment with a favorable prognosis will also be included. Patients who are on anti-TB treatment and severely ill but unable to produce sputum, critically ill patients, and pregnant women will be excluded from the study. Patients who are critically ill are excluded because their condition may cause delays in sample collection and obtaining consent, which would impact the recruitment process. Additionally, pregnant women suspected of TB are excluded since they are managed differently according to TB guidelines.

### Statistical Analysis Plans and Power Calculations (Sample Size)

Based on the preliminary study, the prevalence of fungal coinfections among patients suspected of TB has been previously determined to be 40% using Kish-Leslie formula ( $n = Z^2 P (1-P) / d^2$ ) for determining the sample size in a cross-sectional study. In this formula,  $n$  is the sample size,  $Z$  (1.96) is the statistic for the level of confidence,  $P$  (0.4) is the estimated prevalence, and  $d$  (0.05) is the margin of error for the confidence interval. Using the Open Epi calculator, considering a population of 195,013 for Greater Mbarara, the sample size was determined to be 369 patients. Since we anticipate a 10% dropout rate, we will recruit 406 patients. From these patients, only 2 sputum samples will be collected—an on-spot sample on the day of recruitment and an early morning sample the following day, making a total of 812 samples to be collected. Obtained data will be analyzed using appropriate software, such as GraphPad (GraphPad Software Inc), Stata (StataCorp), or Epi Info (Centers of Disease Control and Prevention), among many others.

### Recruitment Strategy and Retention

Patients will be recruited by convenient sampling as they report for medical services at the HIV/TB clinic of MRRH. The recruitment of the participants will follow the existing diagnosis and point-of-care procedures at both study sites. The clinic receives an average of 10 new cases per day. Considering both



our inclusion and exclusion criteria, we hope to recruit an average of 4 patients per day, resulting in an average total of 88 patients per month. This recruitment plan is achievable based on the rate of patients' inflow at the clinic. Additionally, sputum sample collection is not an invasive method that would scare away patients, so we do not anticipate any major challenges with patient retention. However, we will factor in a possible 10% dropout rate among patients, and thus, the final sample size will be increased by 37 more patients, resulting in a total of 406 patients, as previously mentioned.

### Recruitment Site Selection

We have selected Uganda for this study because the country ranks high among the severely affected nations with HIV and TB pandemics. This is particularly true in western Uganda, where Mbarara (the proposed study site) is located. This subpopulation is also ranked among those most at risk of opportunistic fungal coinfections, yet it has been grossly ignored. Opportunistic pulmonary fungal coinfections are not uncommon among the immunosuppressed cohort, such as patients with HIV. We have selected patients suspected of having TB because most of the opportunistic pulmonary fungal infections present like TB, and therefore, are often missed during routine diagnosis. We have selected Mbarara Hospital as the study site because it is a regional referral hospital for the western region of Mbarara and a treatment center for patients with HIV or TB. Thus, we will have easy access to our study cases due to the high incidence of HIV or TB in this community. However, several population-based studies have been conducted in the past, focusing on HIV and TB, but are not associated with fungal coinfections [33,34]. Additionally, Mbarara University of Science and Technology has the infrastructure to handle most of the study demands. For instance, the Department of Microbiology in the Faculty of Medicine hosts a microbiology laboratory with medical mycology and TB units that have the capacity to respectively perform routine fungal or TB-based sputum analytical protocols, such as TB and GeneXpert testing, potassium hydroxide, and lactophenol cotton blue staining, as well as fungal and bacterial cultures. Additionally, the department has the capacity to do molecular-based procedures, including DNA isolation, polymerase chain reaction (PCR) amplification, and sequencing. The Department of Microbiology has also established collaborations with both national and international institutions, such as the Infectious Diseases Institute of Makerere University, Gulu University, Soroti University, and Muni University in Uganda; Massachusetts General Hospital and University of Minnesota in the United States; University of Birmingham, Sheffield University, and University of Exeter in the United Kingdom; and University of Aberdeen in Scotland.

### Approach and Methodology

#### ***Aim 1: Determining the Burden and Etiological Profiles of Fungal Coinfections Among Patients Suspected of TB***

Patients' sputum samples will be collected and cultured on both fungal and bacterial media for either organism's isolation. The isolates will be identified and profiled accordingly using conventional phenotypic and genomic-based assays. Total DNA

will be extracted from the same sputum samples using a bead-beating phenol-chloroform approach. PCR primers targeting region 2 intergenic transcribed spacer (ITS2) will be used to amplify the fungal DNA present in the sputum samples; the amplified DNA will then be sequenced by Illumina MiSeq technology. This approach has been demonstrated to sensitively identify and determine the relative abundance of all fungi present in similar respiratory samples [35]. In this study, we will use this approach to identify the most abundant fungi present and detect any potential coinfections, which maybe challenging to identify using traditional culture methods. Fungal data will be analyzed using Mothur and the R statistical package PhyloSeq (R Core Team) and will be speciated with reference to the UNITE2 database. Fungal quantitative PCR will be applied to determine the total burden of fungi present in each sample. Shotgun metagenomics will also be applied to a subset of samples. This metagenomics approach will reveal genomic detail of the fungi present, which will potentially include antimicrobial resistance genes and virulence genes and provide further typing information that reveals common clones or transmission among patients. Using long-read technology, the Oxford Nano pore GridION has the advantage of being a rapid sequencing technology that has shown promise as a rapid point-of-care test for the identification of microorganisms in clinical samples. As such, the use of this technology in this study may also reduce the time until diagnosis for fungal infections.

#### ***Aim 2: Establishing and Characterizing Microbial Communities Associated With Patients Suspected of Having TB***

16S ribosomal RNA (rRNA) gene sequencing will be used to target the bacterial communities present in the same samples, using the same DNA extract, to identify bacterial coinfections. The results obtained will be used to describe the bacterial communities present in the sputum samples and then will be integrated with ITS2 fungal data [13,36-38]. To determine the association with the host phenotypes, the clinical metadata, including but not limited to age, gender, BMI, race or tribe, behaviors, and immune status, will be used to determine the association between fungal and bacterial communities with host phenotypes. For correlations between taxa, a combination of 16S rRNA gene and ITS2 sequencing data from the same samples will be used. Co-abundance patterns of bacteria and fungi will reveal potential interactions between and within fungal-bacterial communities, which can be further explored using DNA-independent methods in Aim 3. Both fungal-fungal, bacterial-bacterial and fungal-bacterial relationships will be interrogated using appropriate software packages, such as SparCC [38,39].

#### ***Aim 3: Characterizing Potential Interaction Relationships Established Between Fungal and Bacterial Communities***

We will use a metabolomics approach in which sputum samples will be homogenized with methanol for metabolite extraction and derivatization. The extract and derivatives will then be analyzed for chemical composition using quantitative gas chromatography-mass spectrometry technique based on

metabolite profiling [40]. Gas chromatography-mass spectrometry-based metabolite raw data will be processed using the XCMS toolbox; this processing will involve peak detection, alignment, and multivariate statistical analysis using the XCMS outputs.

We will also attempt to design a genome-scale metabolic model for pulmonary microbial communities to infer the entire microbiome (bacteria and fungi) and host-microbial interactions under different patient conditions. This will be based on the interplays of genes (identified by metagenomics and inferred from amplicon data) and metabolites (identified by metabolomics) by analyzing the full data set and using specific computational tools, including but not limited to Meta-genomic Operationalized Assembly and Annotation Tool 2 for functional categorization and Human Microbiome Project Unified Metabolic Analysis Network 2 for profiling abundance of microbes and activity of their metabolic pathways. A genome-scale model will be developed to explore complex relationships between microbial components, such as genes, using assembly of gut organisms through reconstruction and analysis, a reconstruction-based tool used for microbial-host metabolism, and interactions' analysis [41,42]. In this manner, a genome-scale metabolic model will help us to postulate and test the underlined hypotheses that could link the burden, genotype, and phenotype of pulmonary microbial communities. Through these analyses, we also hope to infer ecological relationships, including but not limited to mutualism, commensalism, competition, antagonism, and symbiosis.

### Expected Deliverables

The following will be expected deliverables to be achieved during the project:

- Total fungal burden in 406 patients and its changes over time (using quantitative PCR)
- Fungal microbiome analysis: relative abundance of sputum fungi and their identity (using ITS2 sequencing)
- Bacterial microbiome analysis: relative abundance of sputum bacteria and their identity (using 16S rRNA gene sequencing)
- Whole community metagenomics: detailed genomic identification and characterization of abundant members of the sputum microbiome, including gene-level detail
- Metabolomics profiling of sputum: analysis of host and microbial metabolites in longitudinal sputum samples
- Integration of culture-dependent and culture-independent data with clinical information to understand disease processes in the patient cohort
- A genome-scale metabolic model of the disease
- Identification of fungal and bacteria in the disease to support subsequent epidemiological, treatment, and basic research investigations
- Training and knowledge transfer in cutting-edge microbiome techniques

### Study Safety

Study participants will be patients with infectious diseases and will be subjected to minimal risks during sample collection. However, the study will involve the collection, handling, and

processing of contagious infectious human biological materials, such as sputum. Additionally, some of the proposed laboratory procedures will involve the use of hazardous reagents, which raise health and safety issues for both study staff and the general environment. However, to mitigate the anticipated risks, we will perform risk assessment procedures to identify the associated risks. Following risk assessment, we will develop standard operating procedures and comply with Control of Substances Hazardous to Health Regulations. These procedures will highlight health and safety measures conforming to the relevant local, national, or international guidelines. To this end, necessary precautions will be taken to ensure that these legislations are followed by both participants and staff involved in the metabolic and molecular ecological evolution of opportunistic pulmonary fungal coinfections (MeMoF) project.

### Study Registration

After a careful audit of the protocol and design, the study was registered in the International Standard Randomized Controlled Trial Number registry (ISRCTN33572982).

### Ethics Approval

The study has been approved by the Uganda National Council of Science and Technology (HS1233ES) and Mbarara University Research Ethics Committee (MUREC1/7-07/09/20) and will be conducted according to Uganda National and European Union legislation.

### Informed Consent

Target patients will be fully informed of the purpose and procedures of this study, their obligations, potential benefits, and risks. To this effect, an informed consent form was prepared and approved by the institutional review board of Mbarara university for use; the form will be signed voluntarily by each of the study participants prior to enrolment.

## Results

Study design, ethical review, approval, and research registration have all been completed. Patient enrollment commenced in March 2022. Most of the enrolled patients have completed their 2 visits. Patient enrollment was completed in June 2023, and the study results will be submitted for publication in late 2023.

We will share the study findings with the department of Microbiology, Faculty of Medicine, Mbarara University of Science and Technology; Ministry of Health Uganda; and other partner nongovernment organizations working with TB and related coinfections. We will discuss the scope, impact, and limitations of pulmonary fungal coinfections and bacterial fungal synergism based on our study findings. We hope to achieve technical and policy-level interventions, conduct capacity building, and increase public awareness of microbial ecological evolution. Finally, we will write abstracts and manuscripts for international conferences to an international audience and for peer-reviewed journals, respectively.

## Discussion

### Expected Findings

We anticipate that the findings of our study will enhance understanding and awareness of invasive pulmonary fungal coinfections among patients suspected of having TB. We hope that the diagnosis of invasive pulmonary fungal infections will improve, thereby advancing patient prognosis. In this study, we highlight an important aspect of cross-kingdom synergism during infection. In particular, we will highlight that fungal-bacterial coinfection is common among the susceptible cohorts of patients, particularly patients suspected of having TB. Our study aims to establish and characterize a network of microbial communities associated with chronic pulmonary diseases, in addition to TB. In doing so, we also hope to characterize potential interaction relationships established between fungal and bacterial coinfecting communities.

### Previous Findings

PTB is the most common opportunistic pulmonary disease, especially among the cohort infected with HIV/AIDS [3,33]. However, the prevalence of TB has been masked by other possible and somewhat endemic infections that can be as common [43-45]. Accordingly, invasive pulmonary fungal coinfections have been highlighted. Several studies show that endemic pulmonary mycoses are not uncommon; however, clinically, many of them manifest with similar signs to TB [45]. This seems to have promoted the misdiagnosis of many pulmonary fungal infections. In other instances of fungal infections, such as aspergillosis, the treatment of PTB is further complicated with residual activation. Thus, in many parts of the world, pulmonary fungal infections continue to be missed or misdiagnosed.

The spectrum of fungal etiology has evolved over the years, expanding from the commonly isolated *Candida* species to encompass clinically rare but commonly environmental opportunists, such as *Cladosporium* spp, *Acremonium* spp, *Alternaria* spp, *Aspergillus* spp, and *Fusarium* spp, among others. This evolutionary event seems to be directly proportional to a recent dramatic increase in predisposing conditions, such as solid organ transplantation, prolonged chemotherapy, and hematological malignancies, which have more than doubled over the last 20 years.

Although the etiology of chronic pulmonary infections is often attributed to *Mycobacterium tuberculosis*, several data reveal that numerous unappreciated fungal opportunists and other non-TB bacterial pathogens can also coinfect or serve as the primary cause of the chronic pulmonary disease [43,45]. Our preliminary hospital data show that up to 92% of patients suspected of having PTB develop pulmonary fungal colonization. Previously, Njovu et al [35] determined a 70.7% prevalence for pulmonary fungal coexistence among patients suspected of having TB. However, the causal profile of disease by most of these cocolonizers has not been explored yet. The challenge is that current diagnostic approaches are not designed to routinely assess polymicrobial infections, and therefore, may fail to detect the presence of fungal-bacterial coinfections.

In this protocol, we hypothesized that cocolonization of a host by multiple microbial communities is influenced by the environmental frequency and antimicrobial resistance profiles of both commensal bacterial and fungal opportunists; furthermore, understanding the nature, diversity, and environmental origin of these communities will provide important insight into their pathological potential. Sadly, not much attention has been given to the possibility of cross-kingdom etiology linking TB and pulmonary mycoses. Polymicrobial infection of the pulmonary system is not uncommon. Importantly, how the different etiological entities influence each other is mostly unknown. However, stemming from the wider environment, we know that bacteria and fungi interact on several levels and can have various effects within each consortium [4,7,17-26]. Yet the impact of these effects is barely known.

Taken together, our data so far suggest that fungal-bacterial coexistence may influence their virulence attributes and antimicrobial resistance patterns, with relevance to patient outcomes. Therefore, in this project, we will investigate how these cross-kingdom synergistic interactions in the wider environment shape the evolutionary trajectories of fungi and bacteria, priming them for antimicrobial resistance and virulence in mammals. Importantly, the diversity of pulmonary infective fungi and bacteria and their complex population structures pose challenges to the analysis and interpretation of conventional data.

### Strengths and Limitations

The main strength of our study is that it is the first research project to integrate fungal-bacterial interactions at the interface of metabolic and molecular ecological evolution of fungal-bacterial etiology that is conducted using direct patient samples. Thus, the methodological setup has been designed to enhance awareness of fungal etiology and fungal-bacterial interactions among patients suspected of having TB. Through this study, we hope to improve the diagnosis and management of pulmonary coinfections. The downside of the study is purely technical; we anticipate a limitation in our methodological approach to study key co-interaction effects of the etiological agents at the metabolic level. This limitation might be associated with our lack of capacity to perform metabolomics experiments.

### Conclusions

We present the protocol of a laboratory-based cross-sectional study involving patients with TB-like symptoms. Through this study, we will explore the metabolic and molecular ecological evolution of invasive opportunistic pulmonary fungal coinfections. This will be achieved by determining the fungal burden, characterizing the associated microbial communities and exploring the potential interaction relationships established between fungal and bacterial etiologies. Through this study, we aim to create diagnostic profile schemes that can be used to infer patient prognostic outcomes in at-risk individuals. Establishing key fungal-bacterial cross-kingdom synergistic relationships is crucial for instituting fungal-bacterial coinfecting etiology.

## Acknowledgments

This study is funded by the European Developing Countries Clinical Trials Partnership (EDCTP) in collaboration with the European Union (grant TMA 2019CDF-2789). The authors also acknowledge the study collaborators from the Birmingham, Exeter, and Sheffield universities in United Kingdom; Infectious Diseases Institute in Makerere university as well as Gulu, Kabale, Soroti, Muni and Busitema universities in Uganda.

## Data Availability

All the data sets generated during this study will be available from the corresponding author as governed by the data-sharing act of Mbarara University of Science and Technology. All generated data sets will be deposited in publically available repositories or published as study manuscripts.

## Authors' Contributions

HI, ERB, MJC, RM, and JKM developed the study concept. HI, ERB, EN, MJC, and LA developed the study design. HI, ERB, IKN, BM, KK, JKM, JSI, PPN, JSK, FB, RK, AB, and BM provided input into the biological sample collection. HI drafted the paper, and all authors read and commented on the paper and agreed on the final version.

## Conflicts of Interest

None declared.

## Multimedia Appendix 1

Peer-review reports from the European & Developing Countries Clinical Trials Partnership (Netherlands).

[\[PDF File \(Adobe PDF File\), 99 KB-Multimedia Appendix 1\]](#)

## References

1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. *Sci Transl Med* 2012 Dec 19;4(165):165rv13 [doi: [10.1126/scitranslmed.3004404](https://doi.org/10.1126/scitranslmed.3004404)] [Medline: [23253612](https://pubmed.ncbi.nlm.nih.gov/23253612/)]
2. Petrikos G, Skiada A, Drogari-Apiranthitou M. Epidemiology of mucormycosis in Europe. *Clin Microbiol Infect* 2014 Jun;20 Suppl 6:67-73 [FREE Full text] [doi: [10.1111/1469-0691.12563](https://doi.org/10.1111/1469-0691.12563)] [Medline: [24476100](https://pubmed.ncbi.nlm.nih.gov/24476100/)]
3. Amiri MRJ, Siami R, Khaledi A. Tuberculosis status and coinfection of pulmonary fungal infections in patients referred to reference laboratory of health centers Ghaemshahr City during 2007-2017. *Ethiop J Health Sci* 2018 Nov 01;28(6):683-690 [FREE Full text] [doi: [10.4314/ejhs.v28i6.2](https://doi.org/10.4314/ejhs.v28i6.2)] [Medline: [30607084](https://pubmed.ncbi.nlm.nih.gov/30607084/)]
4. Frey-Klett P, Burlinson P, Deveau A, Barret M, Tarkka M, Sarniguet A. Bacterial-fungal interactions: hyphens between agricultural, clinical, environmental, and food microbiologists. *Microbiol Mol Biol Rev* 2011 Dec;75(4):583-609 [doi: [10.1128/mmb.00020-11](https://doi.org/10.1128/mmb.00020-11)]
5. Horn F, Üzümlü Z, Möbius N, Guthke R, Linde J, Hertweck C. Draft genome sequences of symbiotic and nonsymbiotic rhizopus microsporus strains CBS 344.29 and ATCC 62417. *Genome Announc* 2015 Feb 26;3(1):e01370-14 [doi: [10.1128/genomea.01370-14](https://doi.org/10.1128/genomea.01370-14)]
6. Husnik F, McCutcheon JP. Functional horizontal gene transfer from bacteria to eukaryotes. *Nat Rev Microbiol* 2018 Feb 27;16(2):67-79 [doi: [10.1038/nrmicro.2017.137](https://doi.org/10.1038/nrmicro.2017.137)] [Medline: [29176581](https://pubmed.ncbi.nlm.nih.gov/29176581/)]
7. Araldi-Brondolo SJ, Spraker J, Shaffer JP, Woytenko EH, Baltrus DA, Gallery RE, et al. Bacterial endosymbionts: master modulators of fungal phenotypes. *Microbiol Spectr* 2017 Sep;5(5) [FREE Full text] [doi: [10.1128/microbiolspec.FUNK-0056-2016](https://doi.org/10.1128/microbiolspec.FUNK-0056-2016)] [Medline: [28936944](https://pubmed.ncbi.nlm.nih.gov/28936944/)]
8. Kalan L, Loesche M, Hodgkinson BP, Heilmann K, Ruthel G, Gardner SE, et al. Redefining the chronic-wound microbiome: fungal communities are prevalent, dynamic, and associated with delayed healing. *mBio* 2016 Nov 02;7(5) [doi: [10.1128/mbio.01058-16](https://doi.org/10.1128/mbio.01058-16)]
9. Mucunguzi J, Mwambi B, Hersi D, Bamanya S, Atuhairwe C, Taremwa I. Prevalence of pulmonary mycoses among HIV infected clients attending anti-retroviral therapy clinic at Kisoro District Hospital, Western Uganda. *IJTDH* 2017 Dec 22;28(1):1-6 [doi: [10.9734/ijtdh/2017/38283](https://doi.org/10.9734/ijtdh/2017/38283)]
10. Connolly JE, McAdams HP, Erasmus JJ, Rosado-de-Christenson ML. Opportunistic fungal pneumonia. *J Thorac Imaging* 1999 Jan;14(1):51-62 [doi: [10.1097/00005382-199901000-00005](https://doi.org/10.1097/00005382-199901000-00005)] [Medline: [9894953](https://pubmed.ncbi.nlm.nih.gov/9894953/)]
11. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. *Clin Microbiol Rev* 2007 Jan;20(1):133-163 [doi: [10.1128/cmr.00029-06](https://doi.org/10.1128/cmr.00029-06)]
12. de Hoog S, Ibrahim AS, Voigt K. Zygomycetes: an emerging problem in the clinical laboratory. *Mycoses* 2014 Dec 31;57 Suppl 3(0 3):1-1 [FREE Full text] [doi: [10.1111/myc.12250](https://doi.org/10.1111/myc.12250)] [Medline: [25175704](https://pubmed.ncbi.nlm.nih.gov/25175704/)]



13. Diaz PI, Strausbaugh LD, Dongari-Bagtzoglou A. Fungal-bacterial interactions and their relevance to oral health: linking the clinic and the bench. *Front Cell Infect Microbiol* 2014 Jul 29;4:101 [FREE Full text] [doi: [10.3389/fcimb.2014.00101](https://doi.org/10.3389/fcimb.2014.00101)] [Medline: [25120959](https://pubmed.ncbi.nlm.nih.gov/25120959/)]
14. Haq I, Zhang M, Yang P, van EJ. Chapter five - The interactions of bacteria with fungi in soil: emerging concepts. *Adv appl microbiol* 2014;89:185-215 [doi: [10.1016/b978-0-12-800259-9.00005-6](https://doi.org/10.1016/b978-0-12-800259-9.00005-6)]
15. Ibrahim A, Gebremariam T, Liu M, Chamilos G, Kontoyiannis D, Mink R, et al. Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis. *J Infect Dis* 2008 Oct 01;198(7):1083-1090 [FREE Full text] [doi: [10.1086/591461](https://doi.org/10.1086/591461)] [Medline: [18694335](https://pubmed.ncbi.nlm.nih.gov/18694335/)]
16. Möbius N, Hertweck C. Fungal phytotoxins as mediators of virulence. *Curr Opin Plant Biol* 2009 Aug;12(4):390-398 [doi: [10.1016/j.pbi.2009.06.004](https://doi.org/10.1016/j.pbi.2009.06.004)] [Medline: [19608453](https://pubmed.ncbi.nlm.nih.gov/19608453/)]
17. Partida-Martinez LP, Hertweck C. Pathogenic fungus harbours endosymbiotic bacteria for toxin production. *Nature* 2005 Oct 06;437(7060):884-888 [doi: [10.1038/nature03997](https://doi.org/10.1038/nature03997)] [Medline: [16208371](https://pubmed.ncbi.nlm.nih.gov/16208371/)]
18. Chamilos G, Lewis RE, Kontoyiannis DP. Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: a hypothesis. *Fungal Genet Biol* 2007 Feb;44(2):88-92 [doi: [10.1016/j.fgb.2006.07.011](https://doi.org/10.1016/j.fgb.2006.07.011)] [Medline: [16990037](https://pubmed.ncbi.nlm.nih.gov/16990037/)]
19. Lackner G, Möbius N, Scherlach K, Partida-Martinez LP, Winkler R, Schmitt I, et al. Global distribution and evolution of a toxigenic burkholderia-rhizopus symbiosis. *Appl Environ Microbiol* 2009 May;75(9):2982-2986 [doi: [10.1128/aem.01765-08](https://doi.org/10.1128/aem.01765-08)]
20. Lackner G, Moebius N, Hertweck C. Endofungal bacterium controls its host by an hrp type III secretion system. *ISME J* 2011 Feb 19;5(2):252-261 [FREE Full text] [doi: [10.1038/ismej.2010.126](https://doi.org/10.1038/ismej.2010.126)] [Medline: [20720578](https://pubmed.ncbi.nlm.nih.gov/20720578/)]
21. Lackner G, Partida-Martinez LP, Hertweck C. Endofungal bacteria as producers of mycotoxins. *Trends Microbiol* 2009 Dec;17(12):570-576 [doi: [10.1016/j.tim.2009.09.003](https://doi.org/10.1016/j.tim.2009.09.003)] [Medline: [19800796](https://pubmed.ncbi.nlm.nih.gov/19800796/)]
22. Mondo SJ, Lastovetsky OA, Gaspar ML, Schwardt NH, Barber CC, Riley R, et al. Bacterial endosymbionts influence host sexuality and reveal reproductive genes of early divergent fungi. *Nat Commun* 2017 Nov 29;8(1):1843 [FREE Full text] [doi: [10.1038/s41467-017-02052-8](https://doi.org/10.1038/s41467-017-02052-8)] [Medline: [29184190](https://pubmed.ncbi.nlm.nih.gov/29184190/)]
23. Salvioli A, Ghignone S, Novero M, Navazio L, Venice F, Bagnaresi P, et al. Symbiosis with an endobacterium increases the fitness of a mycorrhizal fungus, raising its bioenergetic potential. *ISME J* 2016 Jan 5;10(1):130-144 [FREE Full text] [doi: [10.1038/ismej.2015.91](https://doi.org/10.1038/ismej.2015.91)] [Medline: [26046255](https://pubmed.ncbi.nlm.nih.gov/26046255/)]
24. Bonfante P, Desirò A. Who lives in a fungus? The diversity, origins and functions of fungal endobacteria living in Mucoromycota. *ISME J* 2017 Aug 7;11(8):1727-1735 [FREE Full text] [doi: [10.1038/ismej.2017.21](https://doi.org/10.1038/ismej.2017.21)] [Medline: [28387771](https://pubmed.ncbi.nlm.nih.gov/28387771/)]
25. Lastovetsky OA, Gaspar ML, Mondo SJ, LaButti KM, Sandor L, Grigoriev IV, et al. Lipid metabolic changes in an early divergent fungus govern the establishment of a mutualistic symbiosis with endobacteria. *Proc Natl Acad Sci U S A* 2016 Dec 27;113(52):15102-15107 [FREE Full text] [doi: [10.1073/pnas.1615148113](https://doi.org/10.1073/pnas.1615148113)] [Medline: [27956601](https://pubmed.ncbi.nlm.nih.gov/27956601/)]
26. Shaffer JP, U'Ren JM, Gallery RE, Baltrus DA, Arnold AE. An endohyphal bacterium (Chitinophaga, Bacteroidetes) alters carbon source use by *Fusarium keratoplasticum* (F. solani species complex, nectriaceae). *Front Microbiol* 2017 Mar 14;8:350 [FREE Full text] [doi: [10.3389/fmicb.2017.00350](https://doi.org/10.3389/fmicb.2017.00350)] [Medline: [28382021](https://pubmed.ncbi.nlm.nih.gov/28382021/)]
27. Partida-Martinez LP, Flores de Looß C, Ishida K, Ishida M, Roth M, Buder K, et al. Rhizonin, the first mycotoxin isolated from the Zygomycota, is not a fungal metabolite but is produced by bacterial endosymbionts. *Appl Environ Microbiol* 2007 Feb;73(3):793-797 [doi: [10.1128/aem.01784-06](https://doi.org/10.1128/aem.01784-06)]
28. Moebius N, Üzümlü Z, Dijksterhuis J, Lackner G, Hertweck C. Active invasion of bacteria into living fungal cells. *Elife* 2014 Sep 02;3:e03007 [FREE Full text] [doi: [10.7554/eLife.03007](https://doi.org/10.7554/eLife.03007)] [Medline: [25182414](https://pubmed.ncbi.nlm.nih.gov/25182414/)]
29. Itabangi H, Sephton-Clark PC, Tamayo DP, Zhou X, Starling GP, Mahamoud Z, et al. A bacterial endosymbiont of the fungus *Rhizopus microsporus* drives phagocyte evasion and opportunistic virulence. *Curr Biol* 2022 Mar 14;32(5):1115-1130.e6 [FREE Full text] [doi: [10.1016/j.cub.2022.01.028](https://doi.org/10.1016/j.cub.2022.01.028)] [Medline: [35134329](https://pubmed.ncbi.nlm.nih.gov/35134329/)]
30. Sephton-Clark P, Itabangi H, Muñoz J, Voelz K, Cuomo C, Ballou E. Host-pathogen transcriptomics of macrophages, Mucorales and their endosymbionts: a polymicrobial pas de trois. *BioRxiv Preprint posted online Dec 02, 2020.* [doi: [10.1101/580746](https://doi.org/10.1101/580746)]
31. Partida-Martinez L, Groth I, Schmitt I, Richter W, Roth M, Hertweck C. *Burkholderia rhizoxinica* sp. nov. and *Burkholderia endofungorum* sp. nov., bacterial endosymbionts of the plant-pathogenic fungus *Rhizopus microsporus*. *Int J Syst Evol Microbiol* 2007 Nov;57(Pt 11):2583-2590 [doi: [10.1099/ijs.0.64660-0](https://doi.org/10.1099/ijs.0.64660-0)] [Medline: [17978222](https://pubmed.ncbi.nlm.nih.gov/17978222/)]
32. Gee JE, Glass MB, Lackner G, Helsel LO, Daneshvar M, Hollis DG, et al. Characterization of *Burkholderia rhizoxinica* and *B. endofungorum* isolated from clinical specimens. *PLoS One* 2011 Jan 18;6(1):e15731 [FREE Full text] [doi: [10.1371/journal.pone.0015731](https://doi.org/10.1371/journal.pone.0015731)] [Medline: [21267449](https://pubmed.ncbi.nlm.nih.gov/21267449/)]
33. Aturinde A, Farnaghi M, Pilesjö P, Mansourian A. Spatial analysis of HIV-TB co-clustering in Uganda. *BMC Infect Dis* 2019 Jul 12;19(1):612 [FREE Full text] [doi: [10.1186/s12879-019-4246-2](https://doi.org/10.1186/s12879-019-4246-2)] [Medline: [31299907](https://pubmed.ncbi.nlm.nih.gov/31299907/)]
34. Karamagi E, Sensalire S, Muhire M, Kisamba H, Byabagambi J, Rahimzai M, et al. Improving TB case notification in northern Uganda: evidence of a quality improvement-guided active case finding intervention. *BMC Health Serv Res* 2018 Dec 12;18(1):954 [FREE Full text] [doi: [10.1186/s12913-018-3786-2](https://doi.org/10.1186/s12913-018-3786-2)] [Medline: [30541533](https://pubmed.ncbi.nlm.nih.gov/30541533/)]
35. Njovu IK, Musinguzi B, Mwesigye J, Kassaza K, Turigurwa J, Nuwagira E, et al. Status of pulmonary fungal pathogens among individuals with clinical features of pulmonary tuberculosis at Mbarara University Teaching Hospital in Southwestern

- Uganda. Ther Adv Infect Dis 2021 Aug 31;8:20499361211042477 [FREE Full text] [doi: [10.1177/20499361211042477](https://doi.org/10.1177/20499361211042477)] [Medline: [34484738](https://pubmed.ncbi.nlm.nih.gov/34484738/)]
36. Diaz P, Dupuy A, Abusleme L, Reese B, Obergfell C, Choquette L, et al. Using high throughput sequencing to explore the biodiversity in oral bacterial communities. Mol Oral Microbiol 2012 Jun 03;27(3):182-201 [FREE Full text] [doi: [10.1111/j.2041-1014.2012.00642.x](https://doi.org/10.1111/j.2041-1014.2012.00642.x)] [Medline: [22520388](https://pubmed.ncbi.nlm.nih.gov/22520388/)]
  37. Diaz PI, Hong B, Dupuy AK, Strausbaugh LD. Mining the oral mycobiome: methods, components, and meaning. Virulence 2017 Apr 03;8(3):313-323 [FREE Full text] [doi: [10.1080/21505594.2016.1252015](https://doi.org/10.1080/21505594.2016.1252015)] [Medline: [27791473](https://pubmed.ncbi.nlm.nih.gov/27791473/)]
  38. Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome 2017 Nov 25;5(1):153 [FREE Full text] [doi: [10.1186/s40168-017-0373-4](https://doi.org/10.1186/s40168-017-0373-4)] [Medline: [29178920](https://pubmed.ncbi.nlm.nih.gov/29178920/)]
  39. Friedman J, Alm EJ. Inferring correlation networks from genomic survey data. PLoS Comput Biol 2012 Sep 20;8(9):e1002687 [FREE Full text] [doi: [10.1371/journal.pcbi.1002687](https://doi.org/10.1371/journal.pcbi.1002687)] [Medline: [23028285](https://pubmed.ncbi.nlm.nih.gov/23028285/)]
  40. Gao X, Pujos-Guillot E, Martin J, Galan P, Juste C, Jia W, et al. Metabolite analysis of human fecal water by gas chromatography/mass spectrometry with ethyl chloroformate derivatization. Anal Biochem 2009 Oct 15;393(2):163-175 [doi: [10.1016/j.ab.2009.06.036](https://doi.org/10.1016/j.ab.2009.06.036)] [Medline: [19573517](https://pubmed.ncbi.nlm.nih.gov/19573517/)]
  41. Magnúsdóttir S, Heinken A, Kutt L, Ravcheev DA, Bauer E, Noronha A, et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. Nat Biotechnol 2017 Jan 28;35(1):81-89 [doi: [10.1038/nbt.3703](https://doi.org/10.1038/nbt.3703)] [Medline: [27893703](https://pubmed.ncbi.nlm.nih.gov/27893703/)]
  42. Sen P, Orešič M. Metabolic modeling of human gut microbiota on a genome scale: an overview. Metabolites 2019 Jan 28;9(2):22 [FREE Full text] [doi: [10.3390/metabo9020022](https://doi.org/10.3390/metabo9020022)] [Medline: [30695998](https://pubmed.ncbi.nlm.nih.gov/30695998/)]
  43. Denning D, Pleuvry A, Cole D. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Org 2011 Dec 01;89(12):864-872 [doi: [10.2471/blt.11.089441](https://doi.org/10.2471/blt.11.089441)]
  44. Volpe-Chaves CE, Venturini J, B Castilho S, S O Fonseca S, F Nunes T, T Cunha EA, et al. Prevalence of chronic pulmonary aspergillosis regarding time of tuberculosis diagnosis in Brazil. Mycoses 2022 Jul 15;65(7):715-723 [doi: [10.1111/myc.13465](https://doi.org/10.1111/myc.13465)] [Medline: [35524507](https://pubmed.ncbi.nlm.nih.gov/35524507/)]
  45. Zhao Z, Song J, Yang C, Yang L, Chen J, Li X, et al. Prevalence of fungal and bacterial co-infection in pulmonary fungal infections: a metagenomic next generation sequencing-based study. Front Cell Infect Microbiol 2021 Nov 1;11:749905 [FREE Full text] [doi: [10.3389/fcimb.2021.749905](https://doi.org/10.3389/fcimb.2021.749905)] [Medline: [34790588](https://pubmed.ncbi.nlm.nih.gov/34790588/)]

## Abbreviations

**ITS2:** intergenic transcribed spacer 2

**MeMoF:** metabolic and molecular ecological evolution of opportunistic pulmonary fungal coinfections

**MRRH:** Mbarara Regional Referral and Teaching Hospital

**PCR:** polymerase chain reaction

**PTB:** pulmonary tuberculosis

**rRNA:** ribosomal RNA

**TB:** tuberculosis

*Edited by A Mavragani; The proposal for this study was externally peer-reviewed by the European & Developing Countries Clinical Trials Partnership (Netherlands). See the Multimedia Appendix for the peer-review report; Submitted 09.04.23; accepted 26.05.23; published 15.08.23.*

*Please cite as:*

Njovu IK, Nalumaga PP, Ampaire L, Nuwagira E, Mwesigye J, Musinguzi B, Kassaza K, Taseera K, Kiguli Mukasa J, Bazira J, Iramiot JS, Baguma A, Bongomin F, Kwizera R, Achan B, Cox MJ, King JS, May R, Ballou ER, Itabangi H

Investigating Metabolic and Molecular Ecological Evolution of Opportunistic Pulmonary Fungal Coinfections: Protocol for a Laboratory-Based Cross-Sectional Study

JMIR Res Protoc 2023;12:e48014

URL: <https://www.researchprotocols.org/2023/1/e48014>

doi: [10.2196/48014](https://doi.org/10.2196/48014)

PMID: [37581914](https://pubmed.ncbi.nlm.nih.gov/37581914/)

©Israel Kiiza Njovu, Pauline Petra Nalumaga, Lucas Ampaire, Edwin Nuwagira, James Mwesigye, Benson Musinguzi, Kennedy Kassaza, Kabanda Taseera, James Kiguli Mukasa, Joel Bazira, Jacob Stanley Iramiot, Andrew Baguma, Felix Bongomin, Richard Kwizera, Beatrice Achan, Michael J Cox, Jason S King, Robin May, Elizabeth R Ballou, Herbert Itabangi. Originally published in JMIR Research Protocols (<https://www.researchprotocols.org>), 15.08.2023. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted

use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <https://www.researchprotocols.org>, as well as this copyright and license information must be included.